Rodman & Renshaw Initiates Coverage on Quantum BioPharma with $8 Price Target
Event summary
- Rodman & Renshaw initiated coverage on Quantum BioPharma with a BUY rating and a $8 price target on September 17, 2026.
- Quantum BioPharma focuses on neurodegenerative, metabolic, and alcohol misuse disorders with drug candidates in development.
- The company retains 19.48% ownership of Unbuzzd Wellness Inc. and receives 7% royalties on UNBUZZD™ sales until $250 million is reached.
- Quantum's lead compound, Lucid-MS, aims to prevent and reverse myelin degradation in multiple sclerosis.
The big picture
Quantum BioPharma's initiation of coverage by Rodman & Renshaw highlights the growing interest in biotech companies focusing on innovative solutions for challenging disorders. The strategic focus on both clinical development and commercial partnerships, such as the royalty agreement with Unbuzzd Wellness Inc., positions Quantum BioPharma to capitalize on the expanding market for neurodegenerative and metabolic treatments. The $8 price target suggests confidence in the company's ability to deliver on its pipeline and commercialization strategy.
What we're watching
- Clinical Progress
- How the development of Lucid-MS will impact Quantum BioPharma's valuation and strategic positioning in the neurodegenerative disorder space.
- Royalty Revenue
- Whether Quantum BioPharma can sustain significant revenue growth from UNBUZZD™ royalties and achieve the $250 million milestone.
- Market Reception
- The pace at which the market will respond to Rodman & Renshaw's BUY rating and $8 price target.